Moleculin Biotech, Inc. (MBRX)
D
Pipeline Grade
Financial Position (from SEC Filings)
$10.3M
Cash & Equivalents
$6.1M
Quarterly Burn Rate
5 mo
Est. Cash Runway
$12M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
No upcoming catalysts detected for this company.
Active Clinical Trials (2)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT06788756 | L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adu... | PHASE3 | Recruiting | 312 |
| NCT05879250 | WP1066 and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma | PHASE2 | Recruiting | 39 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.
FDA-Related SEC Filings
| Date | Type | Description | Link |
|---|---|---|---|
| 2026-06-30 | 8-K | Moleculin Biotech, Inc. (MBRX) (CIK 0001659617) - EXHIBIT 99.1 | EDGAR |
| 2026-06-05 | 8-K | Moleculin Biotech, Inc. (MBRX) (CIK 0001659617) - EXHIBIT 99.1 | EDGAR |
| 2026-05-29 | 8-K | Moleculin Biotech, Inc. (MBRX) (CIK 0001659617) - EXHIBIT 99.1 | EDGAR |
| 2026-05-22 | 8-K | Moleculin Biotech, Inc. (MBRX) (CIK 0001659617) - EXHIBIT 99.1 | EDGAR |